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Purpose: Topical beta-blocking agents have been used for many years for IOP 
reduction and management of glaucoma. However, there are limited data about their 
efficacy in patients that receive oral beta-blockers concurrently. The aim of this study 
is to evaluate the efficacy and safety of timolol ophthalmic solution in this group of 
patients. 
Methods: This is an observational, prospective, controlled study. 92 patients with 
glaucoma or ocular hypertension will be enrolled and assigned to two groups (46 
patients per group), depending on their systemic beta-blocker treatment status. All 
patients will receive topical timolol maleate for IOP reduction for six months. 
Endpoints: The primary endpoint is mean IOP reduction from baseline at six months 
for each group. Comparisons between groups will be made for heart rate, blood 
pressure, ocular and systemic symptoms as well. 
Conclusion: The results of this study could provide essential information about the 
management of this category of patients and eventually help clinicians to choose more 
effective and safe treatments. 
 
 
Σκοπός: Οι τοπικά χορηγούμενοι β-αποκλειστές χρησιμοποιούνται εδώ και πολλά 
χρόνια για την μείωση της ΕΟΠ και την αντιμετώπιση του γλαυκώματος. Εντούτοις, 
τα δεδομένα είναι περιορισμένα για την αποτελεσματικότητά τους σε ασθενείς που 
λαμβάνουν ταυτόχρονα συστηματικούς β-αποκλειστές. Ο σκοπός αυτής της μελέτης 
είναι η αξιολόγηση της αποτελεσματικότητας και της ασφάλειας της χορήγησης 
οφθαλμικού διαλύματος τιμολόλης στη συγκεκριμένη ομάδα ασθενών. 
Μέθοδοι: Πρόκειται για μια προοπτική, ελεγχόμενη μελέτη παρατήρησης. 92 
ασθενείς με γλαύκωμα ή οφθαλμική υπερτονία θα συμμετέχουν στη μελέτη και θα 
κατανεμηθούν σε δυο ομάδες (46 ασθενείς ανά ομάδα) ανάλογα με το ιστορικό 
λήψης συστηματικών β-αποκλειστών. Όλοι οι ασθενείς θα λάβουν θεραπεία με 
τοπική τιμολόλη για μείωση της ΕΟΠ για έξι μήνες. 
Καταληκτικά σημεία: Το βασικό καταληκτικό σημείο είναι η μέση μείωση της ΕΟΠ 
από την έναρξη στους 6 μήνες στις δυο ομάδες. Συγκρίσεις μεταξύ των ομάδων θα 
γίνουν ως προς τους καρδιακούς παλμούς, την αρτηριακή πίεση, τα οφθαλμικά και 
συστηματικά συμπτώματα. 
Συμπέρασμα: Τα αποτελέσματα αυτής της μελέτης θα μπορούσαν να προσφέρουν 
σημαντικές πληροφορίες για την διαχείριση της συγκεκριμένης κατηγορίας ασθενών 
και ενδεχομένως να βοηθήσουν τους ιατρούς να επιλέγουν πιο αποτελεσματικές και 
ασφαλείς θεραπείες. 
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Glaucoma is a major public health issue. It is the second leading cause of global 
blindness and the most common cause of irreversible blindness (1). It had been 
estimated that approximately 8.4 million people were bilaterally blind from glaucoma 
in 2010 (2). Global prevalence of open-angle glaucoma (OAG), which is the most 
common type, varies from 2.2% to 3% according to recent studies (3, 4). Moreover, a 
large population based study in northern Greece estimated the prevalence of OAG in 
Greek population at 5.5% (5). 
According to European Glaucoma Society: “The open-angle glaucomas are 
chronic, progressive optic neuropathies that have in common characteristic 
morphological changes at the optic nerve head and retinal nerve fibre layer in the 
absence of other ocular disease and congenital anomalies. Progressive retinal ganglion 
cells death and visual field loss are associated with these changes” (6). Several factors 
have been associated with higher risk of OAG development or progression. Intraocular 
pressure (IOP) is one of the most important risk factors. Although high IOP is not 
essential for the diagnosis of glaucoma and not included in the current glaucoma 
definition, it is the only factor to date that could be modified as part of glaucoma 
management. Two large randomized controlled trials provided evidence that 
decreasing IOP in patients with ocular hypertension could be beneficial for the 
prevention of OAG (7, 8). Moreover, the Early Manifest Glaucoma Trial (EMGT) 
suggested that a 25% decrease from baseline IOP could reduce the risk of OAG 
progression by 50% in treated patients (9). 
The aim of glaucoma management currently is IOP lowering. This can be achieved 
by topical or systemic medication and surgical or laser therapies. Topical medication 
is the treatment of choice for patients with early and moderate glacomatous damage. 
There are several agents currently available for topical administration including beta-
receptor antagonists, prostaglandin analogues, carbonic anhydrase inhibitors, alpha2 
selective adrenergic agonists and parasympathomimetics. Beta-blockers were the 
most widely used agents but lately prostaglandin analogues have become first-line 
therapy of glaucoma. However, topical beta-blockers are still administered to a large 
proportion of patients especially as part of fixed combination preparations. 
 
2.2 Timolol maleate 
Timolol maleate is a non-selective beta-adrenergic blocker that was introduced 
in 1970s. It does not have significant intrinsic sympathomimetic, direct myocardial 
depressant, or local anesthetic (membrane-stabilizing) activity. Katz et al were the first 
to describe that a single drop of 0,5% to 1,5% of this drug applied topically produced 
rapid and prolonged lowering of IOP in normal eyes (10). Timolol, like other topical 
beta-blockers, can lower IOP by decreasing the formation of aqueous humor by the 
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ciliary body. Experimental evidence indicates that timolol could act as a beta-
adrenergic antagonist in anterior uveal tissue (which apparently contains beta-
adrenergic receptors). This could inhibit sympathetic tone to the ciliary processes 
which stimulates the formation of aqueous humor (11). The precise mechanism of 
hypotensive mechanism of timolol has not been established yet. 
Several studies have provided evidence about the safety and efficacy of timolol 
and beta-blockers in patients with glaucoma. The mean reduction from baseline IOP 
is approximately 20% to 25% but the drug seems to have its maximum effect during 
waking hours (12, 13).  Topically administered beta-blocker agents are generally well 
tolerated by patients and few ocular side-effects have been reported including corneal 
hypesthesia. However, systemic side effects are much more significant and potentially 
life threatening in rare cases. Although the agent is administered topically, it may gain 
access to the systemic circulation through the lacrimal system or through the 
conjunctival vessels. Blood levels that can be achieved by instillation of beta-blocker 
drops are not as high as those following oral administration but may produce serious 
side effects to predisposed patients (14). Therefore, a full medical history report is 
essential before this type of medicine is prescribed. Contraindications include asthma, 
severe chronic obstructive pulmonary disease, bradycardia, second or third-degree 
heart block and congestive heart failure. In patients with severe impairment of 
myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory 
effect of the sympathetic nervous system necessary to maintain adequate cardiac 
function. Moreover, beta-adrenergic receptor blockade in the bronchi and 
bronchioles results in increased airway resistance from unopposed parasympathetic 
activity. Other categories of reported side-effects include nervous system problems 
such as hallucinations or depression and dermatological problems (alopecia). 
There are many medicinal products containing timolol maleate commercially 
available, most of them in the form of ophthalmic solution and 0.25% or 0,5% 
concentration. Common brand names are Timoptic (Bauch&Laumb), Temserin 
(Vianex), Yesan (Rafarm) and the ophthalmic gel preparation Geltim (Laboratoires 
Thea). Moreover, timolol maleate 0.5% is used in almost every fixed combination 
preparations currently usually combined with a carbonic anhydrase inhibitor. The 
suggested dosage of timolol maleate 0.25% and 0.5% is one drop instillation in the eye 
twice daily. 
 
2.3 Oral beta-blockers and patients with glaucoma 
Patients with glaucoma are usually elderly and frequently face co-existing 
systemic conditions. Data from a retrospective study that examined the medical 
records of 100 patients with OAG suggest that 84% of the patients had one or more 
systemic disorders (15). Systemic hypertension was the most common disorder and 
approximately 20% of all patients received oral beta-blocking agents.
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Oral beta-blockers are used mainly in the management of hypertension, 
arrhythmias and angina pectoris. As mentioned before, the target of these agents is 
the beta-adrenergic receptors which are found within the sympathetic nervous 
system. There are three subclasses of beta receptors. Beta1 receptors are found in 
heart muscle and kidney and when stimulated they increase heart rate and 
contractility and cause release of renin from kidneys. The location of beta2 receptors 
is in smooth muscle causing bronchodilation in the lungs and vasodilation in skeletal 
and cardiac muscle upon stimulation. Beta3 receptors are found in fat cells. Beta-
blocking agents are categorized as selective (affecting only beta1 receptors) and non-
selective (affecting both beta1 and beta2 receptors).  
Systemic beta-receptor blockade could have an impact on IOP as well. It has 
been recently reported that oral beta-blockers may lower IOP by approximately 
1mmHg in patients with no history of medical treatment for glaucoma (16). 
Concurrent administration of topical and oral beta-blocking agents raises safety and 
efficacy questions. In 1979, Batchelor et al. reported no drug interaction or additive 
effect in a small group of patients receiving timolol topically and orally (17). However, 
a retrospective study in 1992 and a post-hoc analysis of data collected from two 
randomized controlled trials in 2000 suggest that the ocular hypotensive effect of 
topical beta-blockers in glaucoma patients receiving oral beta-blockers is significantly 
lower compared to patients that do not receive oral medication (18, 19). In the second 
study, one of the topical agents that were examined was timolol maleate 0.5% and 
the difference of mean IOP reduction between the two groups was estimated at 
1.6mmHg. The precise mechanism responsible for this interaction is not clear but it 
has been suggested that chronic systemic beta-blocker administration could result in 
ciliary body beta-receptor blockade reducing the efficacy of topically administered 
agents. Another possible mechanism could be beta-receptor desensitization.  
 
2.4 Rationale for the study 
Topical beta-blockers are still widely prescribed for the management of 
glaucoma. Additionally, during the past few years fixed combination preparations 
have become a popular choice for treatment as they offer the advantage of two IOP 
lowering agents in a single drop and almost all of them contain timolol maleate. 
Moreover, patients with glaucoma often receive treatment for other coexisting 
conditions. Consequently, concurrent topical and oral administration of beta-blockers 
is not a rare phenomenon. In fact, an Australian study in 2007 estimated that 
approximately 20% of patients with glaucoma received both topical and oral beta-
blocking agents (20). Unfortunately, it is not clear whether the efficacy of topical 
agents is affected in these patients. Limited data from previous reports suggest 
reduced IOP lowering effect but further research is needed. The aim of this study is to 
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examine the efficacy and safety of topical timolol in patients that already receive 
systemic beta-blocking agents. This could provide essential information about the 
management of this category of patients and eventually help clinicians to choose more 




3.  STUDY OBJECTIVES 
 
Primary objective 
To evaluate the IOP lowering efficacy of topically administered timolol maleate 
in patients with previously untreated OAG or ocular hypertension and concurrent 
treatment with systemic beta-blocking agents, compared to patients that do not 
receive systemic beta-blockers, during a follow-up period of six months. 
 
Secondary objectives 
• Evaluation of blood pressure and heart rate 
• Evaluation of ocular discomfort (burning and stinging symptoms) and 
subjective systemic symptoms 
 
 
4. STUDY DESIGN 
 
This is an observational, prospective, controlled study for timolol maleate in 
newly diagnosed and previously untreated patients with OAG or ocular hypertension. 
A total number of 92 patients will be enrolled and assigned to two groups (46 patients 
per group), depending on their systemic beta-blocker treatment status. Patients who 
receive oral beta-blockers will be assigned to the first group and patients who do not 
report recent beta-blocker treatment will be assigned to the second group which is 
the control group. The groups will be matched for age and sex in order to minimize 
confounding factors. The matching ratio will be 1:1. All patients will start receiving 
topical timolol maleate 0.5% drops twice daily for the management of elevated IOP 
and will be followed up for 6 months. The initiation of this treatment for each patient 
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5. ELIGIBILITY CRITERIA 
 
5.1 Inclusion criteria 
Subjects must meet all the following criteria to be eligible for enrolment into 
the study:  
 
• Age over 45 years 
 
• Exhibition of characteristic glaucomatous optic disc damage and visual field 
loss or glaucoma suspect with high risk of glaucoma development (upon 
investigator’s judgement) 
 
• Untreated baseline IOP of 21mmHg or greater and less than 30mmHg in each 
eye and IOP difference within 5mmHg between patient’s eyes (enrolment IOP 
must be verified by two separate measurements) 
 
• No medical history of previous ocular surgery (including laser) except 
uncomplicated phacoemulcification for cataract extraction performed at least 
6 months before enrollment 
 
• Open angle in anterior chamber verified by gonioscopy (grade 3 or 4 of 
Schaffer classification) 
 
• Best corrected visual acuity of 3/10 or better in each eye (Snellen) 
 
• Current treatment with oral beta-blocking agents initiated at least 6 months 
before the study enrolment (for patients assigned to first group) 
 
• Singed informed consent 
 
 
5.2 Exclusion criteria 
Subjects that meet at least one of the following criteria will not be included in 
the study: 
 
• Medical history of conditions that are contradicted for beta-blocker 
administration (asthma, severe chronic obstructive pulmonary disease, 
bradycardia, second or third-degree heart block and congestive heart failure) 
 
• Any type of glaucoma other than primary open-angle glaucoma 
 
• Active external ocular disease, severe dry eye, corneal abnormalities and any 
other condition that could affect the reliability of Goldmann applanation 
tonometry 
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• History of infectious ocular disease, late stage macular degeneration, severe 
diabetic retinopathy or signs of macular oedema 
 
• History of uncontrolled systemic disease (i.e. hypertension or diabetes) 
 
• Central corneal thickness ≤500μm or ≥600μm 
 
• History of any ocular medication (except artificial tears) 1 month before 
enrolment and contact lens users 
 
• History of chronic systemic steroid medication 
 
• History of oral beta-blocking treatment (for patients in control group) 
 
• History of allergic reaction, hypersensitivity or any adverse event to the study 
medication 
 
• Female patients of childbearing potential 
 
• Vertical cup to disk ratio ≥0.8 
 
• Mean deviation (MD) worse than -12dB and sensitivity less than 15dB in the 5 
central degrees of both hemifields in Humphrey 24-2 SITA standard perimetry 
(advanced glaucomatous visual field loss) 
 
• Patients who had participated in a drug research study within 30 days before 
study initiation 
 
Subjects that are unable to understand the study procedures or give informed consent 
will be excluded from participation. Any other reason for patient exclusion is upon 




6. STUDY PROCEDURES 
 
6.1 Enrolment process 
Patients visiting the outpatient clinics of 1st Department of Ophthalmology in 
AHEPA University Hospital of Thessaloniki will be pre-screened and appointed for an 
eligibility screening visit. During this visit, patients will undergo a detailed 
ophthalmologic exanimation and their medical history will be recorded. Optic disc 
imaging and a reliable 24-2 SITA standard visual field test will be performed 
(Humphrey Visual Field Analyzer; Carl Zeiss Meditec Inc.).  Heart rate and blood 
pressure will be measured as well. 
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6.2 Procedures, treatment and follow-up 
Eligible subjects will be appointed for 24h IOP monitoring in ophthalmology 
clinic and IOP fluctuation will be recorded. Patients’ IOP will be measured at 06:00, 
10:00, 14:00, 18:00, 22:00 and 02:00 (±30min). In the next morning at 10:00 (baseline 
visit), IOP, blood pressure and heart rate will be measured again and these will be 
patient’s baseline measurements. After informed consent is signed, patients will be 
instructed how to use the study medication properly. All subjects will receive 1 drop 
of timolol maleate 0.5% sterile ophthalmic solution (Temserin, Vianex A.E.) in each 
eye every 12 hours starting from the day of baseline visit. Patients will be encouraged 
to use the drops at specific hours of the day (09:00±30min and 21:00±30min). Patients 
who receive oral beta-blocking agents (selective or non-selective) will be assigned to 
group 1 and this treatment will remain unchanged during the study. The rest of the 
patients will be assigned to group 2 (control group). Visit 1 will take place 1 month 
later and patients response to the study drug will be evaluated. The anticipated IOP 
lowering effect of timolol is 20% to 25% from baseline. The IOP will be measured and 
recorded at 8:30±30min (before morning instillation) and at 11:00±30min 
(approximately 2h after instillation) and blood pressure and heart rate measurements 
will be recorded. This will be repeated 3 months (visit 2) and 6 months (visit 3) after 
the initiation of the treatment. Visit 3 will be the final visit and a visual field test and 
24h IOP monitoring will be repeated. During all visits patients will undergo a detailed 
ophthalmologic examination and will be questioned about subjective ocular and 
systemic symptoms. After the end of the study patients will continue a follow-up 
schedule according to the stage and progression of their disease. 
 
6.3 Endpoints assessment  
 
Intraocular pressure 
IOP will be measured using calibrated Goldmann applanation tonometry (mmHg units) 
by clinicians masked to patients’ medical history and previous measurements. 
 
Heart rate and blood pressure 
Heart rate and blood pressure will be measured using a calibrated automatic 
electronic sphygmomanometer (beats per minute and mmHg). The same masking 
procedure will be applied in this case as well. 
 
Ocular discomfort 
Ocular discomfort will be evaluated using the ocular surface disease index (OSDI) 
questionnaire which includes 12 questions and a 5-scale grading system (0 to 4) (Walt 
et al, 1997) 
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Subjective systemic symptoms 
Subjective symptoms will be evaluated by a 4-scale grading questionnaire ranging 
from “no”, “mild”, “moderate” to “severe” symptoms (0 to 3). It will include questions 
about general malaise, headaches, fatigue and other symptoms. 
 
6.4 Subject withdrawal 
Subjects are free to withdraw from the study at any time at their own request, 
or they may be withdrawn at any time at the discretion of the investigator for safety 
or behavioural reasons (i.e. rapid disease progression, treatment incompliance). 
Necessary efforts should be made to document subject’s course, outcome and 
potential adverse events, if possible. The investigator is responsible for inquiring the 
reasons for withdrawal. If the subject withdraws from the study, no further 
evaluations should be performed and no additional data should be collected. Any data 
collected before withdrawal of consent can be retained by the investigator/sponsor 
and used for study purposes. 
 
 
7. STATISTICAL ANALYSIS AND CONSIDERATIONS 
 
7.1 Study endpoints 
The primary endpoint is the difference between mean IOP reduction in group 1 
(receiving oral beta-blockers) and mean IOP reduction in group 2 (control group) after 
six months’ treatment with topically administered timolol maleate 0.5% ophthalmic 
solution. For each patient, both eyes will be included in the analysis. 
Secondary endpoints are difference of mean heart rate and blood pressure and 
difference of mean scores for ocular discomfort and systemic symptoms between the 
2 groups at the end of the study. 
 
7.2 Sample size calculation 
As previously mentioned, the primary endpoint of this study is a comparison of 
mean IOP reduction between the two groups. Therefore, this difference will be tested 
using a t-test at P-value (significance level) P=0.05. In a similar study in 2000, Schuman 
et al estimated this difference at 1.6mmHg (less reduction for patients taking beta-
blockers) with a standard deviation for the control group s=2.6. The degree of 
certainty (power of the study) to detect the difference as significant in our study will 
be 80%. The parameters for sample size calculation are the following: 
Δ=1.6                                   s=2.6 
Alpha=0.05                        Critical t=1.96 
Beta=0.2                             Power=0.8 
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Sample size will be calculated according to parameters above and using the following 
type: 
   
 
Δ = |μ2-μ1| = absolute difference between two means  
σ1, σ2 = variance of mean #1 and #2  
n1 = sample size for group #1  
n2 = sample size for group #2  
α = probability of type I error  
β = probability of type II error  
z = critical Z value for a given α or β  
k = ratio of sample size for group #2 to group #1 
 
The result is 41 patients per group or 82 patients in total. However, we should 
anticipate a drop-out rate of approximately 10%, so the final sample size will be: 
n=92 patients in total or 46 patients per group 
 
7.3 Statistical analysis 
Mean IOP reduction will be calculated for each group (final IOP - baseline IOP). 
A per protocol analysis will be followed, so subjects that will withdraw from the study 
will not be included in the analysis. As previously mentioned, IOP will be recorded 
twice during each visit, before and after morning instillation (trough and peak drug 
effect). Therefore, two separate analyses will be performed, one for final trough and 
one for final peak measurement. For the analysis of the primary endpoint, an 
independent samples t-test with significance level P=0.05 will be performed. The same 
test will be used for the comparison of mean heart rate and blood pressure change. 
Demographic characteristics will be presented using descriptive statistics and 
compared between groups. The scores for ocular discomfort and systemic symptoms 
for each group at final visit will be transformed into dichotomous variables (severe – 
not severe) and compared using a x2 test. The software that will be used is IBM SPSS 
Statistics for Windows, Version 24.0 (Armonk, NY: IBM Corp.). 
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8. ADVERSE EVENTS 
 
8.1 Adverse event definition 
An adverse event is any untoward medical occurrence in a clinical investigation 
subject administered a product or medical device: the event needs not necessarily to 
have a causal relationship with the treatment or usage. Adverse events may include: 
• Abnormal test findings 
• Clinically significant symptoms and signs 
• Changes in physical examination findings 
• Hypersensitivity 
• Progression of underlying disease 
 
Additionally, they may include signs or symptoms resulting from: 
• Drug overdose 
• Drug abuse 
• Drug misuse 
• Drug interactions 
• Drug dependency 
• Exposure during pregnancy 
 
 
8.2 Adverse event reporting 
All observed adverse events regardless of suspected causal relationship to study 
medication (timolol maleate) will be recorded. For all adverse events, the 
ophthalmologist must search and obtain information adequate both to determine the 
outcome of the adverse event and to assess whether it meets the criteria for 
classification as a serious adverse event. For adverse events with a causal relationship 
to timolol, follow-up is required until the event resolves or stabilizes at a level 
acceptable to the ophthalmologist. For serious adverse events, the reporting period 
begins from the time that the subject provides informed consent, which is obtained 
prior to the subject’s participation in the study, through the entire study period or 1 
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This study will be conducted in compliance with the protocol, the ethical 
principles set forth in the Declaration of Helsinki, the ICH Guideline E6 for GCP and 
applicable regulatory requirements. Good clinical practice (GCP) is an international 
ethical and scientific quality standard for designing, conducting, recording, and 
reporting research studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety, and 
well-being of study subjects are protected, consistent with the principles that have 
their origin in the Declaration of Helsinki, and that the clinical study data are credible.  
 
9.1. Institutional Review Board/Independent Ethics Committee  
The protocol and any amendments, the subject informed consent and any 
information on compensation for study-related injuries or payment to subjects, will 
receive IRB/IEC approval prior to initiation of the study. During the study, the 
investigator will send to the IRB any reports of adverse events that are serious, 
unlisted and associated with the investigational drug and any new information that 
may adversely affect the safety of the subjects or the conduct of the study. Study 
personnel involved in conducting this study will be qualified by education, training, 
and experience to perform their respective task.  
 
9.2. Informed consent  
Before a subject’s participation in the study, investigator is responsible for 
obtaining freely given consent, in writing, from the subject or a legally acceptable 
representative after adequate explanation of the aims, methods, anticipated benefits, 
and potential hazards of the study and before any protocol-specific procedures or any 
study drugs are administered. The written informed consent form and any other 
written information to be provided to subjects should be revised whenever new 
information becomes available that may be relevant to the subject’s consent. Subjects 
unable to give their written consent may only be enrolled in the study with the consent 
of a legally acceptable representative. The subject must also be informed about the 
nature of the study to the extent compatible with the subject’s understanding. If a 
subject or a subject’s legally acceptable representative is unable to read, an impartial 
witness should be present during the entire informed consent discussion. Subjects 
may withdraw consent from participation in the study at any time. In the event a 
subject withdraws consent to receive study drug, the site may (with the subject’s 
agreement) continue to contact the subject, general practitioner, and any other 
physician or medical care provider for the collection of outcome and survival follow-
up data. 
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9.3. Subject confidentiality  
The investigators and the sponsor will preserve the confidentiality of all subjects 
taking part in the study, in accordance with GCP and local regulations. The investigator 
must ensure that the subject’s anonymity is maintained. Sponsor personnel whose 
responsibilities require access to personal data should agree to keep the identity of 






Executive Committee  
The Executive Committee (EC) consists of members of the academic leadership 
of the study. The EC will be responsible for the conduct of the study including 
addressing any Data Monitoring Committee recommendations and overseeing 
publication of the results.  
 
Independent Data Monitoring Committee  
An independent Data Monitoring Committee (DMC) will monitor the progress of 
the study and ensure that the safety of subjects enrolled in the study is not 
compromised. This committee will review accumulating data on a regular basis, and 
may request to review partially unblinded data. The DMC will make recommendations 
to the Executive Committee regarding the safety of subjects currently enrolled and yet 
to be enrolled in the study.  
 
Clinical Endpoint Committee  
The Clinical Endpoint Committee (CEC), composed of experts in the relevant 
fields, will review all reported study outcomes to provide consistency and validity in 
the assessment of outcomes. Their decisions will be based on blind clinical data and 
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